Ark Genomic (1ARKG) | Stock Overview & Key Data
Ark Genomic Revolution Trust | Mid-cap
Ark Genomic Revolution Trust | Mid-cap
Ark Genomic Performance Comparison
Stock Range
Today's Range
Low: €1.71
High: €1.78
on August 22, 2025
52 Week Range
Low: €1.34
High: €2.53
on May 7, 2025
on February 18, 2025
All-Time High: €80.83 on June 6, 2022
Explore how other NL stocks compare to their 52-week ranges: View NL Market 52-Week Insights
Key Statistics
Market Cap
€175.0M
EPS
5.22
P/E Ratio (TTM)
0.34
Forward P/E
N/A
P/B Ratio
0.03
PEG Ratio
N/A
Div. Yield
N/A
ROE
-209.77%
Beta
N/A
Debt to Equity
1.39
Financial Highlights
Profitability
Gross Margin
72.01%
Operating Margin
0.00%
Profit Margin
64.71%
Returns and Earnings
Return on Assets (TTM)
9.79%
Return on Equity (TTM)
-209.77%
EBITDA
€3.3B
Net Income (TTM)
€522.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€25.90
Quarterly Revenue Growth (YoY)
-2.99%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ark Genomic 1ARKG | 174.98M Mid-cap | 0.56% | 0.00% | 17.88% | -14.42% | -9.64% | -9.64% | -97.39% | -97.20% |
| Wereldhave N.V WHA | 879.00M Mid-cap | 2.37% | 4.97% | 14.46% | 22.58% | 34.94% | 33.80% | 36.59% | 163.16% |
| LS 3X Long 3CON | 850.11M Mid-cap | -2.21% | -61.88% | 3.11% | -23.77% | -57.87% | -64.32% | -93.19% | -90.78% |
| Ferrari Group PLC FERGR | 839.15M Mid-cap | -2.88% | -1.52% | 11.11% | 5.81% | 1.11% | 2.82% | 2.82% | 2.82% |
| AMG Critical AMG | 798.98M Mid-cap | 3.27% | -5.10% | 36.17% | 56.17% | 77.42% | 65.14% | -6.99% | 45.91% |
| Pharming Group N.V PHARM | 788.61M Mid-cap | 15.00% | 36.90% | 22.34% | 29.21% | 19.79% | 57.53% | 1.77% | 8.49% |
Ownership & Short Interest
Insider Ownership
N/A
Institutional Ownership
N/A
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
35K
Average 90-Day Volume
18K
Ark Genomic Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Ark Genomic would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is 1ARKG's 52-week high and low?
- In the last 52 weeks, Ark Genomic reached a high of €2.53 (on February 18, 2025) and a low of €1.34 (on May 7, 2025).
- What is the market cap and P/E ratio for 1ARKG?
- Curious about Ark Genomic's size and valuation? Its market capitalization stands at 174.98M. When it comes to valuation, the P/E ratio (trailing twelve months) is 0.34, and the forward P/E (looking ahead) is N/A.
- Does 1ARKG pay dividends? If so, what's the yield?
- As for dividends, Ark Genomic isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Ark Genomic's main competitors or similar companies to consider before investing?
When looking at Ark Genomic, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Wereldhave N.V
WHA879.00M Real Estate REIT - Retail 33.80% 36.59% LS 3X Long
3CON850.11M N/A N/A -64.32% -93.19% Ferrari Group PLC
FERGR839.15M Industrials Integrated Freight & Logistics 2.82% 2.82% AMG Critical
AMG798.98M Basic Materials Other Industrial Metals & Mining 65.14% -6.99% Pharming Group N.V
PHARM788.61M Healthcare Biotechnology 57.53% 1.77% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ark Genomic Revolution Trust? (e.g., ROE, Debt/Equity)
- To get a sense of Ark Genomic's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -209.77%, the Debt to Equity ratio from the most recent quarter is 1.39, and its Gross Profit Margin stands at 72.01%.
- What is the recent revenue and earnings growth for 1ARKG?
- Looking at Ark Genomic's growth, its revenue over the trailing twelve months (TTM) was €3B. Compared to the same quarter last year (YoY), quarterly revenue grew by -2.99%, and quarterly earnings saw a YoY growth of N/A.
- How much of 1ARKG stock is held by insiders and institutions?
- Wondering who owns Ark Genomic stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.